Your browser doesn't support javascript.
B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response.
Andreano, Emanuele; Paciello, Ida; Pierleoni, Giulio; Piccini, Giulia; Abbiento, Valentina; Antonelli, Giada; Pileri, Piero; Manganaro, Noemi; Pantano, Elisa; Maccari, Giuseppe; Marchese, Silvia; Donnici, Lorena; Benincasa, Linda; Giglioli, Ginevra; Leonardi, Margherita; De Santi, Concetta; Fabbiani, Massimiliano; Rancan, Ilaria; Tumbarello, Mario; Montagnani, Francesca; Sala, Claudia; Medini, Duccio; De Francesco, Raffaele; Montomoli, Emanuele; Rappuoli, Rino.
  • Andreano E; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
  • Paciello I; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
  • Pierleoni G; VisMederi Research S.r.l., Siena, Italy.
  • Piccini G; VisMederi S.r.l, Siena, Italy.
  • Abbiento V; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
  • Antonelli G; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
  • Pileri P; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
  • Manganaro N; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
  • Pantano E; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
  • Maccari G; Data Science for Health (DaScH) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
  • Marchese S; Department of Pharmacological and Biomolecular Sciences DiSFeB, University of Milan, Milan, Italy.
  • Donnici L; INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy.
  • Benincasa L; VisMederi Research S.r.l., Siena, Italy.
  • Giglioli G; VisMederi Research S.r.l., Siena, Italy.
  • Leonardi M; VisMederi Research S.r.l., Siena, Italy.
  • De Santi C; VisMederi S.r.l, Siena, Italy.
  • Fabbiani M; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
  • Rancan I; Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy.
  • Tumbarello M; Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy.
  • Montagnani F; Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy.
  • Sala C; Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Medini D; Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy.
  • De Francesco R; Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Montomoli E; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
  • Rappuoli R; Data Science for Health (DaScH) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Nat Commun ; 14(1): 53, 2023 01 04.
Article in English | MEDLINE | ID: covidwho-2185841
ABSTRACT
The continuous evolution of SARS-CoV-2 generated highly mutated variants able to escape natural and vaccine-induced primary immunity. The administration of a third mRNA vaccine dose induces a secondary response with increased protection. Here we investigate the longitudinal evolution of the neutralizing antibody response in four donors after three mRNA doses at single-cell level. We sorted 4100 spike protein specific memory B cells identifying 350 neutralizing antibodies. The third dose increases the antibody neutralization potency and breadth against all SARS-CoV-2 variants as observed with hybrid immunity. However, the B cell repertoire generating this response is different. The increases of neutralizing antibody responses is largely due to the expansion of B cell germlines poorly represented after two doses, and the reduction of germlines predominant after primary immunization. Our data show that different immunization regimens induce specific molecular signatures which should be considered while designing new vaccines and immunization strategies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: B-Lymphocytes / COVID-19 Vaccines / COVID-19 / Antibody Formation Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2023 Document Type: Article Affiliation country: S41467-022-35781-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: B-Lymphocytes / COVID-19 Vaccines / COVID-19 / Antibody Formation Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2023 Document Type: Article Affiliation country: S41467-022-35781-6